RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit against Lonza Group (LONN.VX) and a number of its affiliates in the U.S. District Court for the District of Delaware. The lawsuit seeks a ruling that Lonzas importation into the United States and the use, offer for sale, and sale in the United States of the GS XceedTM Gene Expression System and CHOK1SV knock-out cell line infringe U.S. Patent No. 8,377,674 (the 674 patent), which applies Precision BioSciences Directed Nuclease EditorTM genome editing technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Lonza from importing the GS XceedTM Gene Expression System and CHOK1SV knock-out cell line into the United States and from using, selling or offering to sell those materials in the United States.

Precision prefers to focus its business development efforts in a positive and productive manner, said Matthew Kane, CEO of Precision BioSciences. However, willful infringement of Precisions proprietary gene editing technology cannot be tolerated. The GS XceedTM Gene Expression System competes directly with Precision's GS knockout system that we developed using our award-winning Directed Nuclease EditorTM technology. We cannot allow Lonza to import, market, and sell a product developed using our intellectual property to customers in the United States without a license to do so.

Today, Precision controls a rapidly growing patent estate consisting of eighteen issued genome engineering patents. Precisions European and Australian patents claim methods that are similar to those claimed in the 674 patent. Certain of the European and Australian patent claims describe methods for modifying DNA in cells, such as the CHOK1SV cell line, using an engineered meganuclease.

About Precision BioSciences

Precision BioSciences mission is to continually provide, improve, and enable the worlds most powerful genome engineering technology. Precisions proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences vision is to be the conduit through which the worlds greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the worlds largest biopharmaceutical and agbiotech firms. Internally, Precision is developing DNE-based products for biologics manufacturing and human therapeutics. For additional information, please visit http://www.precisionbiosciences.com.

Original post:
Precision BioSciences Files Patent Infringement Lawsuit against Lonza Related to GS XceedTM Gene Expression System

Comments are closed.